ArticleClinical cancer research : an official journal of the American Association for Cancer Research2024

First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies.

Nehal J Lakhani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.